Genmab — Maj 2016
-
Men scenariet kan ikke sammenlignes helt. Genmab er special da vi måske kun har set toppen af isbjerget af dens formåen. Hvis den virker i andre sammenhænge taler vi ikke kurs 4t men nærmere 20t. Det gør det sgu svært at sælge også fordi opkøb er en meget reel mulighed. Hvis der kun lå en dobling herfra så ville jeg også finde noget andet.
-
USD 30 m milestone til Genmab
-

-
Første salg af Darzalex i Europa
-
Fantastisk hurtigt må jeg sige
-
Netop Bulder
-
Det er super.
-
Der vil være stort pres på sundhedsmyndighederne for hurtig sagsbehandling.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind